SCHEMBL5246994

SCHEMBL5246994

NC(=O)OCCOCCOCCO

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
TSHR P16473 7/20 0.50
MAPK1 P28482 1/20 0.50
CHRM2 P08172 2/20 0.43
CHRM4 P08173 2/20 0.43
CHRM5 P08912 2/20 0.43
CHRM1 P11229 2/20 0.43
CHRM3 P20309 2/20 0.43
LMNA P02545 2/20 0.43
CHRNB2 P17787 2/20 0.43
CHRNA4 P43681 2/20 0.43
HTR1A P08908 1/20 0.43
CYP2C19 P33261 1/20 0.43
CHRNA7 P36544 1/20 0.43
ALOX15 P16050 1/20 0.40
ALDH1A1 P00352 4/20 0.39
TP53 P04637 2/20 0.39
HIF1A Q16665 2/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2781589 1.00 MEN1 (0.55) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL29283281 1.00 MEN1 (0.55) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL29009042 1.00 MEN1 (0.55) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL1013720 1.00 MEN1 (0.55) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL28536719 1.00 MEN1 (0.55) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL24835739 0.89 TSHR (0.50) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL31591142 0.89 TSHR (0.50) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL30552236 0.89 TSHR (0.50) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL22326177 0.89 MEN1 (0.48) MEN1KMT2ATSHRMAPK1CHRM2
SCHEMBL22326195 0.89 MEN1 (0.48) MEN1KMT2ATSHRMAPK1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118103074-A Cytotoxic targeting chimeras for CCR2 expressing cells 葛兰素史克知识产权发展有限公司 2024-05-28 CN disclosed
US-11981894-B2 Antisense nucleic acids NIPPON SHINYAKU CO., LTD. (JP) 2024-05-14 US disclosed
CN-118019750-A Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2024-05-10 CN disclosed
CN-117677399-A Effective ASGPR binding compounds for the degradation of immunoglobulins and other proteins 阿维拉治疗公司 2024-03-08 CN disclosed
CN-112672993-B Novel AUTOTAC chimeric compounds and compositions comprising same for preventing, ameliorating or treating diseases by targeted protein degradation 奧土择破利悟株式会社 2024-03-08 CN disclosed
CN-112368289-B C26-linked rapamycin analogues as MTOR inhibitors 锐新医药公司 2024-02-20 CN disclosed
CN-112638477-B Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication 共晶制药公司 2024-01-26 CN disclosed
CN-117136076-A MCL-1 inhibitor antibody drug conjugates and methods of use 诺华股份有限公司 2023-11-28 CN disclosed
CN-115380026-B Protein degradation modulators and methods of use thereof 南京明德新药研发有限公司 2023-11-07 CN disclosed
CN-115916194-A Methods for delaying, preventing and treating acquired resistance to RAS inhibitors 锐新医药公司 2023-04-04 CN disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 CN disclosed
US-20200123177-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. 2020-04-23 US disclosed
EP-3615545-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION Cocrystal Pharma, Inc. (US) 2020-03-04 EP disclosed
WO-2020023813-A1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. (US) 2020-01-30 WO disclosed
WO-2020022785-A1 NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME 주식회사 프로텍바이오 2020-01-30 WO disclosed
CN-110637022-A Pyrrolopyrimidine derivatives as inhibitors of influenza virus replication 共晶制药公司 2019-12-31 CN disclosed
WO-2018200425-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA, INC. (US) 2018-11-01 WO disclosed
EP-1379598-B1 UNSATURATED COMPOUNDS CONTAINING CARBAMATE TERMINAL GROUPS OR UREA TERMINAL GROUPS BASF AG (DE) 2007-09-12 EP disclosed
US-6916854-B2 Heat and/or light curable films or coatings comprising polyurethanes or polyureaurethane copolymers having storage stability, used as automobile paints BASF AKTIENGESELLSCHAFT (DE) 2005-07-12 US disclosed
US-20040097642-A1 Unsaturated compounds containing carbamate terminal groups or urea terminal groups BASF AKTIENGESELLSCHAFT (DE) 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981894-B2 Antisense nucleic acids UTRN, RBM17, UPF1 MEN1 4228/4885KMT2A 3365/4885TSHR 3607/4885
US-20200123177-A1 PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION ITPA, POLR2H, POLR2E MEN1 4650/4885KMT2A 2703/4885TSHR 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.